Related Experiment Video
Updated: Feb 27, 2026

09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.8K
Persistent sacral chloroma in refractory acute myelogenous leukaemia
Scott Mathew McCarty1, Dennis John Kuo1
1Pediatric Hematology-Oncology, University of California, San Diego, California, USA.
BMJ Case Reports
|July 9, 2017
Summary
Acute myelogenous leukemia (AML) can present as chloromas. This case suggests the sacral spinal canal may be a sanctuary site for AML, persisting despite chemotherapy.
Area of Science:
- Hematology
- Oncology
- Pediatric Oncology
Background:
- Acute myelogenous leukemia (AML) is a cancer of the myeloid line of white blood cells.
- Chloromas, also known as myeloid sarcomas, are extramedullary tumors composed of leukemic cells and are a distinctive manifestation of AML.
- Certain sites like the central nervous system, bone marrow, and testes are recognized sanctuary sites for AML, where the disease can persist despite treatment.
Observation:
- A 14-year-old boy diagnosed with AML presented with multiple chloromas at initial diagnosis.
- While extra-calvarial masses and bone marrow disease responded to chemotherapy, sacral epidural chloromas showed resistance.
- The patient received four courses of chemotherapy, yet the sacral epidural chloromas remained.
Findings:
- This case highlights the potential for chloromas to develop in the sacral epidural space.
- The persistence of sacral epidural chloromas despite multiple chemotherapy courses suggests refractoriness to standard treatment.
- The findings indicate that the sacral spinal canal could represent an additional sanctuary site for acute myelogenous leukemia.
Implications:
- The sacral spinal canal should be considered a potential sanctuary site in pediatric AML with chloromas.
- Further investigation into the unique biology and treatment resistance of chloromas in this location is warranted.
- This case may inform treatment strategies for AML patients presenting with extramedullary disease, particularly in the spinal canal.

